Reccurence of endometrioid ovarian cysts and possible ways to its reduce

In: Gynecology · 2020 · vol. 22(3) , pp. 34–38 · doi:10.26442/20795696.2020.3.200144 · W3040695824
article OA: gold CC0 ⤵ 3 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-08

This study compared hormone therapies for endometrioid cyst recurrence, finding significantly lower recurrence rates with hormone therapy (3.75%) compared to no therapy (38.1%), with dienogest showing the lowest relapse rate after discontinuation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Aim. Comparative evaluation of the effectiveness of various types of hormone therapy for the prevention of relapses of endometrioid cysts (EC), based on clinical observation and data analysis. Materials and methods. Retrospective analysis of 122 patients (the average age 31.76.12 years) with laparoscopically confirmed endometriosis. Patients were divided into groups, according to the treatment options aGnRH (n=11), COCs (n=13), dienogest (Visanne) (n=56). A comparison group included 42 patients who did not receive hormone therapy. There were evaluated the number of reccurence in the group without therapy and in groups with different options for hormonal therapy. Results. Among patients treated with hormone therapy, the recurrence rate of EC was 3.75%, among those who have not received therapy 38.1%. Of these, 31.1% of patients had recurrence rate of EC during the first year, 37.8% during 3 years, and 31.1% after 3 years. After suppressive therapy was discontinued, the relapse rate in the aGnRH group was 63.6%, COC 50%, dienogest 24%. Conclusions. In addition to evaluating the ovarian reserve before and after surgical treatment, management tactics for patients with EC should include the long-term administration of dienogest as an anti-relapse therapy.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (3)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK